GET MORE AI-GENERATED SIGNALS: November 10, 2024, 17:44 pm ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...

Technical analysis for Ascendis Pharma A/s ASND including support levels resistance levels and stop losses for ASND ...

Below is Validea's guru fundamental report for ASCENDIS PHARMA A/S (ADR) (ASND). Of the 22 guru strategies we follow, ASND rates highest using our Small-Cap Growth Investor model based on the ...

In a report released today, Li Watsek from Cantor Fitzgerald maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...

Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a ...

On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

European equities traded in the US as American depositary receipts were moving higher late Monday morning, rising 0.35% to 1,339.76 on the S&P Europe Select ADR Index. From continental Europe, the ...